Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?
Phio Pharmaceuticals unveils findings on PH-762, a promising candidate for cancer therapy. Discover its rapid cell uptake and tumor-inhibiting potential.
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
Eli Lilly expands its global manufacturing network with FDA-approved facility acquisition in Pleasant Prairie, Wisconsin. Boosting production to meet growing demand for medicines, including GLP-1 drugs.
Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?
Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.
What’s Going On With Nano-Cap NKGen Biotech Stock On Monday?
Latest on NKGen Biotech Inc (NASDAQ: NKGN) as shares surge 25.2% on high volume. Insights into NK cell therapy for neurodegenerative diseases. Developments in Parkinson's and Alzheimer's treatments.
Phio’s Intratumoral Injection Of PH-762 Significantly Inhibits Tumor Growth In Murine Tumor Models And May Generate Memory-Specific T Cells; Injection In Murine Tumors Shows The Compound Is Well Tolerated
-Injection in murine tumors shows the compound is well tolerated-Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinomaMARLBOROUGH, Mass.,
Legend Biotech Announces Carvykti Approved By The European Commission For Second-Line Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, announced
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the upcoming medical conference in June.
‘The U.S Supreme Court Has Reportedly Declined To Hear Vanda Pharmaceuticals’ Case Regarding The Invalidation Of Certain Patents For Its Sleep-Wake Disorder Drug Hetlioz, That Were Previously Declared Invalid In A Dispute With Generic Drugmakers Teva A…
https://finance.yahoo.com/news/1-u-supreme-court-rejects-153720025.htmlThe U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were
Changing Frugal Eating Habits – How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits.
HeartCore Expands Partnership With Heart-Tech Health To Implement AI Capabilities Into Its Med-Tech Platform.
HeartCore Enterprises, Inc. (NASDAQ:HTCR) ("HeartCore" or the "Company"), a leading enterprise software and consulting services company based in Tokyo, announced its Artificial Intelligence (AI) Software Development